SilverbergMSSatsangiJAhmadTArnottIDBernsteinCNBrantSR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
2.
WintherKVFøghPThomsenOØBrynskovJ. Inflammatory bowel disease (ulcerative colitis and Crohn’s disease): diagnostic criteria and differential diagnosis. Drugs Today (Barc). 1998;34(11):935-942.
3.
YeBDJangBIJeenYTLeeKMKimJSYangSK; IBD, et al. [Diagnostic guideline of Crohn’s disease]. Korean J Gastroenterol. 2009;53(3):161-176.
4.
BernsteinCNEliakimAFedailS, et al. World Gastroenterology Organisation global guidelines inflammatory bowel disease. J Clin Gastroenterol. 2016;50(10):803-818.
5.
World Gastroenterology Organisation. World Gastroenterology Organisation Global Guideline: Inflammatory Bowel Disease: A Global Perspective. Munich, Germany: World Gastroenterology Organisation; 2009. http://guideline.gov/content.aspx?id=15231
WilsonAReyesEOfmanJ. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116(suppl 7A):44S-49S.
8.
KoutroubakisIERamos-RiversCRegueiroM, et al. Persistent or recurrent anemia is associated with severe and disabling inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13(10):1760-1766.
9.
FilmannNReyJSchneeweissSArdizzoneSBagerPBergamaschiG, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20(5):936-945.
10.
ChildJABrozovićBDyerNHMollinDLDawsonAM. The diagnosis of iron deficiency in patients with Crohn’s disease. Gut. 1973;14(8):642-648.
11.
LeeMWPourmoradyJSLaineL. Use of fecal occult blood testing as a diagnostic tool for clinical indications: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115:662-670.
12.
PetersonCGEklundETahaYRaabYCarlsonM. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97(7):1755-1762.
13.
SipponenTSavilahtiEKärkkäinenPKolhoKLNuutinenHTurunenU, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-α therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14:1392-1398.
14.
TibbleJASigthorssonGBridgerSFagerholMKBjarnasonI. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22.
15.
CostaFMumoloMGCeccarelliLBelliniMRomanoMRSterpiC, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54(3):364-368.
16.
WaughNCumminsERoylePKandalaNBShyangdanDArasaradnamR, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17(55):xv-xix1.
17.
VermeireSVan AsscheGRutgeertsP. Laboratory markers in IBD: useful, magic, or unnecessary toys. Gut. 2006;55(3):426-431.
18.
Denis FranchimontMD. C-reactive protein: informative or misleading marker of Crohn’s disease?Inflam Bowel Dis. 2007;13(4):501-502.
19.
SharmaYBousvarosALiuEBender SternJ. Natural history of children with mild Crohn’s disease. World J Gastroenterol. 2019;25(30):4235-4245.
20.
LobelEZKorelitzBIVakherKPanagopoulosG. Prolonged remission of severe Crohn’s disease after fever and leukopenia caused by 6-mercaptopurine. Dig Dis Sci. 2004;49(2):336-338.
